Seminars in Hematology
Volume 43 , Pages S22-S26 , April 2006

Role of Single-Agent Purine Analogues in Therapy of Peripheral T-Cell Lymphomas

  • Claire E. Dearden

      Affiliations

    • Corresponding Author InformationAddress correspondence to Claire E. Dearden, MD, FRCP, MRCPath, The Royal Marsden Hospital and Institute of Cancer Research, London SM2 5PT, UK

References 

  1. Rudiger T , Weisenburger DD , Anderson JR , Armitage JO , Diebold J , MacLennan KA , et al.   Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma) (Results from the Non-Hodgkin’s Lymphoma Classification Project) . Ann Oncol . 2002;13:140–149
  2. Matutes E , Brito-Babapulle V , Swansbury J , Ellis J , Morilla R , Dearden C , et al.   Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia . Blood . 1991;78:3269–3274
  3. Matutes E , Taylor GP , Cavenagh J , Pagliuca A , Bareford D , Domingo A , et al.   Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma (Response and outcome in 15 patients) . Br J Haematol . 2001;113:779–784
  4. Garand R , Goasguen J , Brizard A , Buisine J , Charpentier A , Claisse JF , et al.   Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d’Hematologie Cellulaire . Br J Haematol . 1998;103:488–494
  5. Liu JH , Wei S , Lamy T , Epling-Burnette PK , Starkebaum G , Djeu JY , et al.   Chronic neutropenia mediated by fas ligand . Blood . 2000;95:3219–3222
  6. Manns A , Hisada M , La Grenade L . Human T-lymphotropic virus type I infection . Lancet . 1999;353:1951–1958
  7. Broder S , Bunn PA , Jaffe ES , Blattner W , Gallo RC , Wong-Staal F , et al.   NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus . Ann Intern Med . 1984;100:543–557
  8. Lepretre S , Buchonnet G , Stamatoullas A , Lenain P , Duval C , d’Anjou J , et al.   Chromosome abnormalities in peripheral T-cell lymphoma . Cancer Genet Cytogenet . 2000;117:71–79
  9. Giblett ER , Anderson JE , Cohen F , Pollara B , Meuwissen HJ . Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity . Lancet . 1972;2:1067–1069
  10. Yu AL , Mendelsohn J , Matsumoto SS . Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A) . Adv Exp Med Biol . 1986;195:491–496
  11. Spiers AS , Ruckdeschel JC , Horton J . Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms . Scand J Haematol . 1984;32:130–134
  12. Spiers AS , Davis MP , Levine M , Li CY , Mangan KF , Mazza JJ , et al.   T-cell chronic lymphocytic leukaemia (Anomalous cell markers, variable morphology, and marked responsiveness to pentostatin (2′-deoxycoformycin)) . Scand J Haematol . 1985;34:57–67
  13. Ho AD , Suciu S , Stryckmans P , De Cataldo F , Willemze R , Thaler J , et al.  Leukemia Cooperative Group   Pentostatin in T-cell malignancies—A phase II trial of the EORTC . Ann Oncol . 1999;10:1493–1498
  14. el’Agnaf MR , Ennis KE , Morris TC , Robertson JH , Markey G , Alexander HD . Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia . Br J Haematol . 1986;63:93–104
  15. Dohner H , Ho AD , Thaler J , Stryckmans P , Sonneveld P , de Witte T , et al.   Pentostatin in prolymphocytic leukemia (Phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group) . J Natl Cancer Inst . 1993;85:658–662
  16. Dearden C , Matutes E , Catovsky D . Pentostatin treatment of cutaneous T-cell lymphoma . Oncology (Williston Park) . 2000;14:37–40
  17. Dearden C , Matutes E , Catovsky D . Deoxycoformycin in the treatment of mature T-cell leukaemias . Br J Cancer . 1991;64:903–906
  18. Mercieca J , Matutes E , Dearden C , MacLennan K , Catovsky D . The role of pentostatin in the treatment of T-cell malignancies (Analysis of response rate in 145 patients according to disease subtype) . J Clin Oncol . 1994;12:2588–2593
  19. Tsimberidou AM , Giles F , Duvic M , Fayad L , Kurzrock R . Phase II study of pentostatin in advanced T-cell lymphoid malignancies (Update of an M.D. Anderson Cancer Center series) . Cancer . 2004;100:342–349
  20. O’Brien S , Kurzrock R , Duvic M , Kantarjian H , Stass S , Robertson LE , et al.   2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders . Blood . 1994;84:733–738
  21. Lorand-Metze I , Oliveira GB , Aranha FJ . Treatment of prolymphocytic leukemia with cladribine . Ann Hematol . 1998;76:85–86
  22. Rondelli D , Lauria F , Zinzani PL , Raspadori D , Ventura MA , Galieni P , et al.   2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders . Eur J Haematol . 1997;58:46–50
  23. Tobinai K , Uike N , Saburi Y , Chou T , Etoh T , Masuda M , et al.   Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma . Int J Hematol . 2003;77:512–517
  24. Uike N , Choi I , Tokoro A , Goto T , Yufu Y , Kozuru M , et al.   Adult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine . Intern Med . 1998;37:411–413
  25. Sallah AS , Bernard S . Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2-chlorodeoxyadenosine . Ann Hematol . 1996;73:295–296
  26. Witzig TE , Weitz JJ , Lundberg JH , Tefferi A . Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues . Leuk Lymphoma . 1994;14:137–139
  27. Kantarjian HM , Childs C , O’Brien S , Huh Y , Beran M , Schachner J , et al.   Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia . Am J Med . 1991;90:223–228
  28. Whelan JS , Davis CL , Rule S , Ranson M , Smith OP , Mehta AB , et al.   Fludarabine phosphate for the treatment of low grade lymphoid malignancy . Br J Cancer . 1991;64:120–123
  29. Weidmann E , Boehrer S , Chow KU , Engels K , Harder L , Hinz T , et al.   Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine . Onkologie . 2001;24:162–164
  30. Dumontet C , Morschhauser F , Solal-Celigny P , Bouafia F , Bourgeois E , Thieblemont C , et al.   Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin’s lymphoma . Br J Haematol . 2001;113:772–778
  31. Sallah S , Wan JY , Nguyen NP . Treatment of refractory T-cell malignancies using gemcitabine . Br J Haematol . 2001;113:185–187
  32. Zinzani PL , Baliva G , Magagnoli M , Bendandi M , Modugno G , Gherlinzoni F , et al.   Gemcitabine treatment in pretreated cutaneous T-cell lymphoma (Experience in 44 patients) . J Clin Oncol . 2000;18:2603–2606
  33. Zinzani PL , Magagnoli M , Bendandi M , Orcioni GF , Gherlinzoni F , Albertini P , et al.   Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients . Ann Oncol . 1998;9:1351–1353
  34. Marchi E , Alinari L , Tani M , Stefoni V , Pimpinelli N , Berti E , et al.   Gemcitabine as frontline treatment for cutaneous T-cell lymphoma (Phase II study of 32 patients) . Cancer . 2005;104:2437–2441
  35. Talpur R , Apisarnthanaraz N , Ward S , Kerne H , Chiao N , Kurzrock R , et al.   Phase II Evaluation of gemcitabine as a single agent for cutaneous T-cell lymphoma . Blood . 2003;102:404a; (abstr)
  36. Goy A , Bleyer A , Hagemeister F , Fayad PB , Romaguera J , Samaniego F , et al.   Phase II study of compound GW506U78 (AraG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treatment with chemotherapy . Blood . 2003;102:639a; (abstr)
  37. Dearden CE , Matutes E , Cazin B , Tjonnfjord GE , Parreira A , Nomdedeu B , et al.   High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H . Blood . 2001;98:1721–1726
  38. Dillman RO , Beauregard J , Shawler DL , Halpern SE , Markman M , Ryan KP , et al.   Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma . J Biol Response Mod . 1986;5:394–410
  39. Knox S , Hoppe RT , Maloney D , Gibbs I , Fowler S , Marquez C , et al.   Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody . Blood . 1996;87:893–899
  40. Saven A , Carrera CJ , Carson DA , Beutler E , Piro LD . 2-Chlorodeoxyadenosine (An active agent in the treatment of cutaneous T-cell lymphoma) . Blood . 1992;80:587–592
  41. Kuzel TM , Hurria A , Samuelson E , Tallman MS , Roenigk HH , Rademaker AW , et al.   Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma . Blood . 1996;87:906–911
  42. Kong LR , Samuelson E , Rosen ST , Roenigk HH , Tallman MS , Rademaker AW , et al.   2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders . Leuk Lymphoma . 1997;26:89–97
  43. Betticher DC , Ratschiller D , Hsu Schmitz SF , von Rohr A , Hess U , Zulian G , et al.  Swiss Group for Clinical Cancer Research (SAKK)   Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia . Ann Oncol . 1998;9:721–726
  44. Von Hoff DD , Dahlberg S , Hartstock RJ , Eyre HJ . Activity of fludarabine monophosphate in patients with advanced mycosis fungoides (A Southwest Oncology Group study) . J Natl Cancer Inst . 1990;82:1353–1355
  45. Redman JR , Cabanillas F , Velasquez WS , McLaughlin P , Hagemeister FB , Swan F , et al.   Phase II trial of fludarabine phosphate in lymphoma (An effective new agent in low-grade lymphoma) . J Clin Oncol . 1992;10:790–794

PII: S0037-1963(05)00265-9

doi: 10.1053/j.seminhematol.2005.12.008

Seminars in Hematology
Volume 43 , Pages S22-S26 , April 2006

Article Tools